Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 701-704

  D'Arena, Giovanni ^a   Cascavilla, Nicola ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; PREDNISONE; RITUXIMAB; ROMIPLOSTIM; VINCRISTINE;

AGED; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PLATELET COUNT; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 79953224842     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.542598     Document Type: Article

References (15)

1. Hamblin TJ. Autoimmune complications of chronic lympho-cytic leukemia. Semin Oncol 2006;33:230-239.
2. Dearden C. Disease-specific complications of chronic lym-phocytic leukemia. Hematology 2008;2008:450-456.
3. Visco C, Ruggeri M, Evangelista ML, et al. Impact ofimmune thrombocytopenia on the clinical course of chronic lympho-cyticleukemia. Blood 2008;111:1110-1116. (Pubitemid 351213389)
4. Gernshmeimer TB. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombo-poietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology 2008;2008: 219-226.
5. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy ofromiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371: 395-403. (Pubitemid 351181334)
6. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet 2009;373:641-648.
7. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplos-tim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171.
8. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004;25:52-60. (Pubitemid 38018897)
9. Stasi R, Evangelisti ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008;68:901-912. (Pubitemid 351652920)
10. Salch MN, Bussel JB, Cheng G, et al. Eltrombopag is efficacious in patients with refractory chronic idiopathic thrombocytopenic purpura (ITP)-data from the EXTEND Study. Blood 2008;112(Suppl. 1):Abstract 401.
11. Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia. Leukemia 2010;24:1096-1098.
12. Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol 2010;47:289-298.
13. Chouhan ID, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy 2010;30:666-683.
14. Bowen DA, Call TG, Shanafeklt TD, et al. Treatment of autoimmune cytopenias complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620-627.
15. Kaufman M, Rai K. The challenge of treating complex autoimmune cytopenias in chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:574-575.